Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America

Brazilian Journal of Infectious Diseases

Volumn 18, Issue 4, 2014, Pages 421-433

  Guzmán Blanco, Manuel ^a   Labarca, Jaime A ^b   Villegas, Maria Virginia ^c   Gotuzzo, Eduardo ^d  

^a Hospital Vargas de Caracas   (Venezuela)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Bacterial resistance; Escherichia coli; Klebsiella; Latin America

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; OXYIMINO CEPHALOSPORIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; BETA LACTAMASE CTX M 2; BETA LACTAMASE CTX M 8; BETA LACTAMASE CTX M 9; BETA LACTAMASE SHV; BETA LACTAMASE SHV 12; BETA LACTAMASE SHV 5;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BOLIVIA; BRAZIL; CHILE; COLOMBIA; CONTROL STRATEGY; DOMINICAN REPUBLIC; ECUADOR; EL SALVADOR; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GUATEMALA; HONDURAS; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MEXICO; NICARAGUA; NONHUMAN; PANAMA; PARAGUAY; PERU; PREVALENCE; PUERTO RICO; REVIEW; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; VENEZUELA; ASSISTED VENTILATION; BACTERIAL GENETICS; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; ENTEROBACTER CLOACAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GASTROSTOMY; HOSPITAL ADMISSION; INFECTION CONTROL; INTENSIVE CARE UNIT; JEJUNOSTOMY TUBE; PROTEUS MIRABILIS; RISK FACTOR; SERRATIA MARCESCENS; SHORT SURVEY;

BACTERIAL RESISTANCE; ESCHERICHIA COLI; KLEBSIELLA; LATIN AMERICA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CROSS INFECTION; ENTEROBACTERIACEAE; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 84904042954     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.10.005     Document Type: Short Survey

References (79)

1. World Health Organization Report on the burden of endemic health care-associated infection worldwide 2011, Available at http://whqlibdoc.who.int/publications/2011/9789241501507_eng.pdf [accessed 20.12.11].
2. European Centre for Disease Prevention and Control Annual epidemiological report Reporting on 2009 surveillance data and 2010 epidemic intelligence data 2011, Available at http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=767 [accessed 17.07.12].
3. Allegranzi B., Bagheri Nejad S., Combescure C., et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011, 377:228-241.
4. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
5. Falagas M.E., Bliziotis I.A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. Int J Antimicrob Agents 2007, 29:630-636.
6. Savard P., Perl T.M. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis 2012, 25:371-377.
7. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
8. Mendes R.E., Rhomberg P.R., Bell J.M., Turnidge J.D., Sader H.S. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis 2009, 63:415-425.
9. Biedenbach D.J., Moet G.J., Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004, 50:59-69.
10. Andrade S.S., Sader H.S., Jones R.N., Pereira A.S., Pignatari A.C., Gales A.C. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?. Mem Inst Oswaldo Cruz 2006, 101:741-748.
11. Casellas J.M. Resultados encuesta número 7. Rev Panam Infectol 2006, 8:48-51.
12. Casellas J.M. Resistencia a los antibacterianos en América Latina: consecuencias para la infectología. Rev Panam Salud Publica 2011, 30:519-528.
13. Gales A.C., Sader H.S., Jones R.N. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002, 44:289-299.
14. Guzmán-Blanco M., Casellas J.M., Sader H.S. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin North Am 2000, 14:67-81.
15. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
16. Bush K., Jacoby G.A. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010, 54:969-976.
17. Casellas J.M., Quinteros M.G. A Latin American "point de vue" on the epidemiology, control, and treatment options of infections caused by extended-spectrum beta-lactamase producers. Antimicrobial resistance in bacteria 2006, Horizon Bioscience, Wymondham. C.F. Amabile-Cuevas (Ed.).
18. Canton R., Coque T.M. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
19. Casellas J.M., Goldberg M. Incidence of strains producing extended spectrum beta-lactamases in Argentina. Infection 1989, 17:434-436.
20. Gonzalez-Vertiz A., Alcantar-Curiel D., Cuauhtli M., et al. Multiresistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infection. Infect Control Hosp Epidemiol 2001, 22:723-725.
21. Otman J., Cavassin E.D., Perugini M.E., Vidotto M.C. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unit in Brazil. Infect Control Hosp Epidemiol 2002, 23:8-9.
22. Sader H.S., Gales A.C., Pfaller M.A., et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 2001, 5:200-214.
23. Turner P.J. Extended-spectrum beta-lactamases. Clin Infect Dis 2005, 4(41 Suppl.):S273-S275.
24. Ben-Ami R., Rodríguez-Baño J., Arslan H., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690.
25. Quinteros M., Radice M., Gardella N., et al. Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 2003, 47:2864-2867.
26. Villegas M.V., Correa A., Perez F., et al. CTX-M-12 beta-lactamase in a Klebsiella pneumoniae clinical isolate in Colombia. Antimicrob Agents Chemother 2004, 48:629-631.
27. Rossi F., Baquero F., Hsueh P.R., et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006, 58:205-210.
28. Baquero F., Hsueh P.R., Paterson D.L., et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2009, 10:99-104.
29. Villegas M.V., Blanco M.G., Sifuentes-Osornio J., Rossi F. Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America-2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis 2011, 15:34-39.
30. Hawser S.P., Bouchillon S.K., Hoban D.J., et al. Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009). J Chemother 2012, 24:6-11.
31. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007, 60:1018-1029.
32. Fernández-Canigia L., Dowzicky M.J. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010. Ann Clin Microbiol Antimicrob 2012, 11:29.
33. Gales A.C., Castanheira M., Jones R.N., Sader H.S. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012, 73:354-360.
34. Pan-American Health Organization Informe Anual de la Red de Monitoreo/Vigilancia de la Resistencia a los Antibióticos - 2006 2006, Available at http://www2.paho.org/hq/dmdocuments/2009/amr_2006_informe_anual.pdf [accessed 06.03.13].
35. Pan-American Health Organization Informe Anual de la Red de Monitoreo/Vigilancia de la Resistencia a los Antibióticos/2009 2009, Available at http://new.paho.org/hq/index.php?option=com_content&view=article&id=6221&Itemid=4328&lang=en [accessed 06.03.13].
36. Hoban D.J., Nicolle L.E., Hawser S., Bouchillon S., Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011, 70:507-511.
37. Gaitan C.S., Espinal M.P. Molecular characterization of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae in hospitals of the Caribean Region. Colombia Rev Chilena Infectol 2009, 26:239-246.
38. Garza-Gonzalez E., Mendoza Ibarra S.I., Llaca-Diaz J.M., Gonzalez G.M. Molecular characterization and antimicrobial susceptibility of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey. Mexico J Med Microbiol 2011, 60:84-90.
39. Morfin-Otero R., Mendoza-Olazaran S., Silva-Sanchez J., et al. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum beta-lactamase. Microb Drug Resist 2013.
40. Marcano D., De Jesús A., Hernández L., Torres L. Frequency of enzymes associated with reduced sensitivity to beta-lactam antibiotics in enterobacteria isolates, Caracas, Venezuela. Rev Panam Salud Publica 2011, 30:529-534.
41. da Silva Dias R.C., Borges-Neto A.A., D'Almeida Ferraiuoli G.I., de-Oliveira M.P., Riley L.W., Moreira B.M. Prevalence of AmpC and other beta-lactamases in enterobacteria at a large urban university hospital in Brazil. Diagn Microbiol Infect Dis 2008, 60:79-87.
42. Navarro-Navarro M., Robles-Zepeda R.E., Garibay-Escobar A., Ruiz-Bustos E. Hospital and community-acquired beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae at hospitals in Hermosillo. Sonora Salud Publica Mex 2011, 53:341-344.
43. Tedesco Maiullari R.M., Guevara A. Enterobacteria producers of extended-spectrum beta-lactamase in a hospital from Venezuela. Infez Med 2012, 20:93-99.
44. Quiñones D., Valverde A., Rodriguez-Banos M., et al. High clonal diversity in a non-outbreak situation of clinical ESBL-producing Klebsiella pneumoniae isolates in the First National Surveillance Program in Cuba. Microb Drug Resist 2013.
45. Wollheim C., Guerra I.M., Conte V.D., et al. Nosocomial and community infections due to class A extended-spectrum beta-lactamase (ESBLA)-producing Escherichia coli and Klebsiella spp. in southern Brazil. Braz J Infect Dis 2011, 15:138-143.
46. Nogueira Kda S., Higuti I.H., do Nascimento A.J., et al. Occurrence of extended-spectrum beta-lactamases in Enterobacteriaceae isolated from hospitalized patients in Curitiba, southern Brazil. Braz J Infect Dis 2006, 10:390-395.
47. Mena P., González A.J.C., Josefina M. Extended spectrum beta-lactamase detection in Enterobacteriaceae family strains. Kasmera 2009, 37:25-37.
48. Sennati S., Santella G., Di Conza J., et al. Changing epidemiology of extended-spectrum beta-lactamases in Argentina: emergence of CTX-M-15. Antimicrob Agents Chemother 2012, 56:6003-6005.
49. Celenza G., Pellegrini C., Caccamo M., Segatore B., Amicosante G., Perilli M. Spread of bla(CTX-M-type) and bla(PER-2) beta-lactamase genes in clinical isolates from Bolivian hospitals. J Antimicrob Chemother 2006, 57:975-978.
50. Poirel L., Naas T., Le Thomas I., Karim A., Bingen E., Nordmann P. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 2001, 45:3355-3361.
51. Dropa M., Balsalobre L.C., Lincopan N., et al. Extended-spectrum beta-lactamases among Enterobacteriaceae isolated in a public hospital in Brazil. Rev Inst Med Trop Sao Paulo 2009, 51:203-209.
52. Pulido I.Y., Mantilla J.R., Valenzuela E.M., Reguero M.T., Gonzalez E.B. Distribution of extended spectrum beta-lactamases-codifying genes in Klebsiella pneumoniae isolates from hospitals of Bogota, DC, Colombia. Biomedica 2011, 31:15-20.
53. Bello H., Trabal N., Ibanez D., et al. Beta-lactamases other than TEM and SHV among strains of Klebsiella pneumoniae subsp pneumoniae isolated from Chilean hospitals. Rev Med Chil 2005, 133:737-739.
54. Casellas J.M. Resultados de la 7a Encuesta del Comité de Resistencia a Antimicrobianos de la Asociación Panamericana de Infectología. Rev Panam Infectol 2006, 8:48-55.
55. Silva F.O., Cifuentes M., Pinto E.C. Results of antimicrobial susceptibility surveillance in Chile: consolidating a network. Rev Chile Infect 2011, 28:19-27. representing the Collaborative Group on Antimicrobial Resistance.
56. Briceño D.F., Correa A., Valencia C., et al. Antimicrobial resistance of Gram negative bacilli isolated from tertiary-care hospitals in Colombia. Biomedica 2010, 30:371-381.
57. Cohen-Nahum K., Saidel-Odes L., Riesenberg K., Schlaeffer F., Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 2010, 38:41-46.
58. Wu U.I., Yang C.S., Chen W.C., Chen Y.C., Chang S.C. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 2010, 43:310-316.
59. Cassier P., Lallechere S., Aho S., et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital. Clin Microbiol Infect 2011, 17:1746-1751.
60. Paterson D.L., Ko W.C., Von Gottberg A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004, 140:26-32.
61. Saely S., Kaye K.S., Fairfax M.R., Chopra T., Pogue J.M. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Infect Control 2011, 39:390-395.
62. Bhavnani S.M., Ambrose P.G., Craig W.A., Dudley M.N., Jones R.N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006, 54:231-236.
63. Mosqueda-Gómez J.L., Montaño-Loza A., Rolón A.L., et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. Int J Infect Dis 2008, 12:653-659.
64. Muro S., Garza-Gonzalez E., Camacho-Ortiz A., et al. Risk factors associated with extended-spectrum beta-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis. Chemotherapy 2012, 58:217-224.
65. Levy S.S., Mello M.J., Gusmao-Filho F.A., Correia J.B. Colonisation by extended-spectrum beta-lactamase-producing Klebsiella spp. in a paediatric intensive care unit. J Hosp Infect 2010, 76:66-69.
66. Bermejo J., Bencomo B., Arnesi N., Lesnaberes P., Borda N., Notario R. High relationship between ciprofloxacin use and prevalence of ESBL Klebsiella pneumoniae. Rev Chilena Infectol 2006, 23:316-320.
67. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
68. O'Brien T.F., Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clin Microbiol Rev 2011, 24:281-295.
69. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996, 22:387-394.
70. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
71. Andrade V., Silva J. Characterization of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in an intensive care unit. Salud Publica Mex 2004, 46:524-528.
72. Casellas J.M., Nannini E., Radice M., et al. Estudio de un brote debido a aislados de Klebsiella pneumoniae productores de betalactamasas de espectro extendido en un centro asistencial de Rosario - Argentina. Rev Panam Infectol 2005, 7:21-27.
73. Galvis C.E., Mariñoa A.C., Monroy J., Posso Y.H. The impact of an antibiotic restriction policy in the intensive care unit at the hospital militar central. Rev Med 2008, 2008.
74. Furtado G.H., Perdiz L.B., Onita J.H., Wey S.B., Medeiros E.A. Correlation between rates of carbapenem consumption and the prevalence of carbapenem-resistant Pseudomonas aeruginosa in a tertiary care hospital in Brazil: a 4-year study. Infect Control Hosp Epidemiol 2010, 31:664-666.
75. Zilberberg M.D., Chen J., Mody S.H., Ramsey A.M., Shorr A.F. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010, 10:45.
76. Papadimitriou-Olivgeris M., Marangos M., Fligou F., et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 2012, 67:2976-2981.
77. Harris A.D., Kotetishvili M., Shurland S., et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007, 35:97-101.
78. Harris A.D., Perencevich E.N., Johnson J.K., et al. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis 2007, 45:1347-1350.
79. González A.C.R., Gil F.G., Solórzano M.R., et al. Outbreak of multiresistant and extended spectrum β-lactamase producing Klebsiella pneumoniae in a high risk neonatal unit. Rev Chil Infectol 2011, 28:28-34.